

Generic (Brand)	Dosing: Hospitalized patients	Dosing: NON-Hospitalized Pts - Mild to Moderate Tx *Reserve for high risk of clinical progression*	Dosing: PREexposure / POSTexposure Prophylaxis	Renal adjustment
Remdesivir (Veklury)	IV: 200 mg x1 on day 1, then 100 mg once daily. Start within 72 hours of a positive test. Use with dexamethasone and/or baricitinib. Duration: 5 days or until hospital discharge, may extend up to 10 days for certain patients	IV: 200 mg x1 on day 1, then 100 mg once daily on days 2 and 3. Initiate within 7 days of symptom onset.		eGFR <30: No safety data
Baricitinib (Olumiant)	Oral: 4 mg once daily. Use with corticosteroids and/or remdesivir. Duration: 14 days or until hospital discharge			eGFR 30-59: 2 mg once daily eGFR 15-29: 1 mg once daily. eGFR <15: Use is not recommended.
Tocilizumab (Actemra)	IV: 8 mg/kg (pts ≥30 kg) or 12 mg/kg (pts <30 kg) x1 (max: 800 mg/dose), use with glucocorticoids . May give ≥8 hours after the first dose, if no clinical improvement Criteria: Limit to patients on systemic corticosteroids and require supp O2, non-invasive or invasive mechanical ventilation, or ECMO.			CrCl <30: No recc by Mfg
Bamlanivimab ¹		IV ≥40 kg: 700 mg x1; administer ASAP after a positive test and within 10 days of symptom onset.		None
Bamlanivimab/etesevimab ¹		IV: Bamlanivimab 700 mg and etesevimab 1.4 g x1; administer ASAP after a positive test and within 10 days of symptom onset	POSTexposure prophylaxis IV: Bamlanivimab 700 mg and etesevimab 1.4 g x1; administer ASAP following exposure	None
Casirivimab/imdevimab (Regeneron) ¹		IV (preferred), SUBQ (alternative): Casirivimab 600 mg and imdevimab 600 mg x1; administer ASAP after a positive test and within 10 days of symptom onset	POSTexposure prophylaxis IV, SUBQ: Casirivimab 600 mg and imdevimab 600 mg x1; administer ASAP following exposure. May repeat casirivimab 300 mg and imdevimab 300 mg once every 4 weeks for pts with ongoing exposure not expected to mount an adequate immune response to complete vaccination.	None
Tixagevimab/cilgavimab (Evusheld)			PREexposure prophylaxis IM: Tixagevimab 150 mg and cilgavimab 150 mg x1, ≥2 weeks after vaccination. May be repeated every 6 months for at risk individuals Criteria: Immune compromised and may not be able to mount an adequate response to COVID-19 vaccination, or history of severe adverse reaction to the vaccine.	None
Nirmatrelvir/Ritonavir (Paxlovid)		Oral: Nirmatrelvir 300 mg with ritonavir 100 mg, twice daily for 5 days; initiate within 5 days of symptom onset		eGFR 30-59: Nirmatrelvir 150 mg and ritonavir 100 mg BID eGFR <30: Not recommended
Molnupiravir		Oral: 800 mg every 12 hours for 5 days; initiate within 5 days of symptom onset.		None

¹ Not authorized for pts who require new or increased respiratory support as outcomes may worsen